Found: 37
Select item for more details and to access through your institution.
Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation.
- Published in:
- EMBO Journal, 2002, v. 21, n. 8, p. 1967, doi. 10.1093/emboj/21.8.1967
- By:
- Publication type:
- Article
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22115-1
- By:
- Publication type:
- Article
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 4, p. 337, doi. 10.1038/nbt.2157
- By:
- Publication type:
- Article
A simple method to cure established tumors by inflammatory killing of normal cells.
- Published in:
- Nature Biotechnology, 2004, v. 22, n. 9, p. 1125, doi. 10.1038/nbt1007
- By:
- Publication type:
- Article
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.
- Published in:
- Nature Medicine, 2013, v. 19, n. 12, p. 1625, doi. 10.1038/nm.3397
- By:
- Publication type:
- Article
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.
- Published in:
- Nature Medicine, 2012, v. 18, n. 9, p. 1445, doi. 10.1038/nm0912-1445d
- By:
- Publication type:
- Article
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.
- Published in:
- Nature Medicine, 2008, v. 14, n. 1, p. 37, doi. 10.1038/nm1681
- By:
- Publication type:
- Article
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.
- Published in:
- Nature Medicine, 2005, v. 11, n. 10, p. 1073, doi. 10.1038/nm1297
- By:
- Publication type:
- Article
Inactivation of Replication-Competent Vesicular Stomatitis Virus as SARS-CoV-2 Surrogate on Common Surfaces by Disinfectants.
- Published in:
- International Journal of Environmental Research & Public Health, 2021, v. 18, n. 14, p. 7714, doi. 10.3390/ijerph18147714
- By:
- Publication type:
- Article
Factors Affecting Topotecan Sensitivity in Human Leukemia Samples<sup>a</sup>.
- Published in:
- Annals of the New York Academy of Sciences, 1996, v. 803, n. 1, p. 128, doi. 10.1111/j.1749-6632.1996.tb26382.x
- By:
- Publication type:
- Article
Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus.
- Published in:
- Molecular Therapy, 2014, v. 22, n. 10, p. 1851, doi. 10.1038/mt.2014.118
- By:
- Publication type:
- Article
The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site.
- Published in:
- Molecular Therapy, 2014, v. 22, n. 11, p. 1936, doi. 10.1038/mt.2014.134
- By:
- Publication type:
- Article
Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse.
- Published in:
- Molecular Therapy, 2013, v. 21, n. 8, p. 1507, doi. 10.1038/mt.2013.116
- By:
- Publication type:
- Article
The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-treated Mice.
- Published in:
- Molecular Therapy, 2013, v. 21, n. 2, p. 348, doi. 10.1038/mt.2012.204
- By:
- Publication type:
- Article
Phase II Trial of Intravenous Administration of Reolysin<sup>®</sup> (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma.
- Published in:
- Molecular Therapy, 2012, v. 20, n. 10, p. 1998, doi. 10.1038/mt.2012.146
- By:
- Publication type:
- Article
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1279387
- By:
- Publication type:
- Article
Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1757, doi. 10.1093/neuonc/noaa126
- By:
- Publication type:
- Article
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 4, p. 518, doi. 10.1093/neuonc/nov173
- By:
- Publication type:
- Article
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
- Published in:
- Science Translational Medicine, 2018, v. 10, n. 422, p. 1, doi. 10.1126/scitranslmed.aam7577
- By:
- Publication type:
- Article
Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.
- Published in:
- International Journal of Cancer, 2012, v. 131, n. 4, p. 844, doi. 10.1002/ijc.26447
- By:
- Publication type:
- Article
Unbiased selection of bone marrow derived cells as carriers for cancer gene therapy.
- Published in:
- Journal of Gene Medicine, 2007, v. 9, n. 11, p. 927, doi. 10.1002/jgm.1089
- By:
- Publication type:
- Article
Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy.
- Published in:
- Molecular Therapy, 2011, v. 19, n. 10, p. 1802, doi. 10.1038/mt.2011.147
- By:
- Publication type:
- Article
Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide.
- Published in:
- Molecular Therapy, 2011, v. 19, n. 1, p. 140, doi. 10.1038/mt.2010.224
- By:
- Publication type:
- Article
VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 Signaling.
- Published in:
- Molecular Therapy, 2011, v. 19, n. 1, p. 150, doi. 10.1038/mt.2010.225
- By:
- Publication type:
- Article
Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy.
- Published in:
- Molecular Therapy, 2009, v. 17, n. 10, p. 1667, doi. 10.1038/mt.2009.194
- By:
- Publication type:
- Article
Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer.
- Published in:
- Molecular Therapy, 2008, v. 16, n. 12, p. 1910, doi. 10.1038/mt.2008.212
- By:
- Publication type:
- Article
Treg Depletion–enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus.
- Published in:
- Molecular Therapy, 2008, v. 16, n. 7, p. 1217, doi. 10.1038/mt.2008.83
- By:
- Publication type:
- Article
56. The Efficacy of Replicating Virotherapy for Tumors Involves a Complex Equilibrium between Virus, Tumor and the Immune System.
- Published in:
- Molecular Therapy, 2006, v. 13, p. S24, doi. 10.1016/j.ymthe.2006.08.071
- By:
- Publication type:
- Article
262. Delivery of CCL21 to Metastatic Disease Improves the Efficacy of Adoptive T Cell Therapy.
- Published in:
- Molecular Therapy, 2006, v. 13, p. S100, doi. 10.1016/j.ymthe.2006.08.316
- By:
- Publication type:
- Article
421. Killing of Normal Cells Combined with TLR Engagement and CD40 Ligation Generates Autoimmune T Cell Reactivity Sufficient To Treat Large Established Tumors.
- Published in:
- Molecular Therapy, 2006, v. 13, p. S162, doi. 10.1016/j.ymthe.2006.08.486
- By:
- Publication type:
- Article
723. VSV-G Pseudotyped, Semi-Replication Competent MLV Retroviruses for Cancer Gene Therapy
- Published in:
- 2005
- By:
- Publication type:
- Abstract
449. Tumor Targeted, Systemic Delivery of Therapeutic Viral Vectors Using Hitch Hiking on Antigen Specific T Cells
- Published in:
- 2005
- By:
- Publication type:
- Abstract
267. Inflammatory Killing of Normal Cells To Treat Metastatic Tumors
- Published in:
- 2005
- By:
- Publication type:
- Abstract
271. Interactions between Replicating Virotherapy and Tumor Growth in the Presence of an Intact Immune System
- Published in:
- 2005
- By:
- Publication type:
- Abstract
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-14568-7
- By:
- Publication type:
- Article
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
- Published in:
- BMC Cancer, 2011, v. 11, n. 1, p. 221, doi. 10.1186/1471-2407-11-221
- By:
- Publication type:
- Article